Clinical

Articles

Results of 2 recent studies suggested a higher risk of developing osteoporosis in patients with inflammatory bowel disease.

Inflammatory Bowel Disease May Increase Risk of Osteoporosis

Kevin W. Chamberlin, PharmD, is associate clinical professor and assistant department head, pharmacy practice, University of Connecticut School of Pharmacy, Storrs, Conn.

An overview of the use of satralizumab-mwge (Enspryng; Genentech) in neuromyelitis optica spectrum disorder (NMOSD).

Satralizumab-mwge for Neuromyelitis Optica Spectrum Disorder in Adults

Two lots of the thyroid tablets are being recalled after testing found the lots to be subpotent. 

Acella Recalls 2 Lots of Thyroid Medication for Subpotency

Higher cumulative exposure to systemic antibiotic therapy may be associated with a greater risk of new-onset inflammatory bowel disease.

Antibiotics Linked to Higher Risk of Inflammatory Bowel Disease

Pharmacists can play an important role in educating patients about autoimmune drugs to prevent medication errors.

Prevent Medication Errors in Autoimmune Disease

Levodopa/carbidopa is currently the gold standard for controlling motor symptoms associated with Parkinson disease. 

Opicapone Can Help Treat Patients Experiencing “Off” Episodes With Parkinson Disease

Ofatumumab (Kesimpta; Novartis) is the first and only self-administered, targeted B-cell therapy for the treatment of relapsing multiple sclerosis. 

FDA OKs Ofatumumab for Treatment of Relapsing Multiple Sclerosis

The therapy received fast track designation and was approved in just over 1 year. 

FDA Approves Satralizumab-mwge for Treatment of Rare Autoimmune Disease

Frieda Wiley, PharmD, BCGP, is a writer and pharmacist. 

A Kawasaki-like inflammatory disease has affected children who have coronavirus disease 2019.

Investigators Find COVID-19 Connection in Vasculitis

The data from a new study has shown that investigational, long-acting injectable cabotegravir boasted a 66% higher efficacy than daily oral pills in preventing HIV-1.

Investigational Long-Acting Injectable Cabotegravir Shows Superior Efficacy Over Daily Oral PrEP

A new study found increased plaque buildup levels in women with HIV who also suffered from persistent depression and stress. 

Women With HIV and Persistent Depression May Experience Greater Risk for Heart Disease

In studies presented this month at the European E-Congress of Rheumatology 2020, investigators revealed positive findings for the infliximab biosimilar CT-P13 (Inflectra, Remsima), which is developed by Celltrion of Incheon, Republic of Korea.


Studies Reveal Positive Results for Infliximab Biosimilar

A recent analysis showed a surge in prescription fills for hydroxychloroquine/chloroquine, likely due to off-label prescribing for coronavirus disease 2019. 

Prescription Fills Surge for Hydroxychloroquine, Chloroquine During Pandemic

Ixekizumab (Taltz, Eli Lilly) is the first interleukin-17A antagonist to be approved for non-radiographic axial spondyloarthritis.

FDA Approves Ixekizumab for Non-radiographic Axial Spondyloarthritis 

Bristol Myers Squibb announced the commercial US launch of ozanimod (Zeposia) for the treatment of relapsing forms of multiple sclerosis.

New Oral Treatment for Relapsing Forms of Multiple Sclerosis Now Available

Filgotinib achieved all primary end points of the phase 2b/3 study in patients with moderate-to-severe ulcerative colitis.

Filgotinib Trial Shows Positive Results in Ulcerative Colitis 

Dupilumab (Dupixent, Sanofi and Regeneron) is the first biologic medicine approved for treatment of moderate-to-severe atopic dermatitis.

FDA Approves Dupilumab for Atopic Dermatitis in Children 

Apremilast (Otezla, Amgen) significantly improved psoriasis symptoms compared with a placebo in adults with mild-to-moderate disease.

Phase 3 Study: Apremilast Shows Efficacy in Mild-to-Moderate Plaque Psoriasis 

Rituximab-abbs (Truxima) is the only biosimilar to the reference product rituximab (Rituxan). 

Rituximab Biosimilar Now Available in United States for Rheumatoid Arthritis

Six-year data from the new analyses add evidence to the benefit-risk profile of ocrelizumab (Ocrevus, Genentech) for patients with multiple sclerosis. 

Autoimmune Diseases